Our dongle
A brief overview of Telomir Pharmaceuticals
Telomir Pharmaceuticals (TELO) has filed proposed terms to raise $7 million through the sale of its common stock in an initial public offering, according to an amended SEC registration statement.
The company is a Preclinical-stage biopharmaceutical company developing treatments for age-related inflammatory diseases.
I have already written about Telomir's initial application here.
Given TELO's small capitalization, high valuation expectations, and early stage of development, my opinion on the IPO is Sell. [Avoid].
Telomir Pharmaceuticals – Overview and Market
Telomir Pharmaceuticals, Inc., based in Tampa, Florida, is developing small molecules as an “oral in situ therapeutic treatment for human stem cells.”
The Company is led by Chairman and CEO Christopher Chapman, Jr., MD, who has been with the Company since November 2022 and is currently Executive Chairman of MIRA Pharmaceuticals (MIRA) and has many years of experience Experience in the pharmaceutical industry.
The company's lead candidate is TELOMIR-1, and the company believes it has the potential to act as an interleukin-17 inhibitor, which could play a role in age-related inflammatory conditions such as hemochromatosis and osteoarthritis, as well as post-chemotherapy health problems. '
Telomir has recorded a total fair market value investment of $6.9 million from investors as of September 30, 2023.
The hemochromatosis treatment market was estimated to be worth $901 million in 2022.
It is expected to grow 6% from 2022 to 2029 and reach nearly $1.35 billion, according to a report by Maximize Market Research.
Several factors are expected to drive the growth of the market including increasing awareness and diagnosis of hemochromatosis diseases as well as increasing healthcare expenditure.
However, strict regulatory processes and limited accessibility can slow market growth.
The market is also influenced by the increasing use of tests to detect iron overload, such as serum transferrin saturation and blood ferritin tests.
Advances in the detection of liver disease, such as a simple, naked-eye method for glycocholic acid [GCA] detection, are likely to further drive the market.
Some of the key players in this market include Pfizer, Global Calcium, Fresenius Kabi USA, Novartis, Sun Pharma, Teva Pharmaceuticals, Taro Pharmaceuticals, Merck KGaA, Apo Pharma and Livealth Biopharma, among others.
The following graphic shows the competitive landscape of management for its hemochromatosis therapy:
SEC
Financial Position of Telomir Pharmaceuticals
The company's recent financial results are typical of a preclinical-stage biopharmaceutical company, as they show zero revenue and increasing general, administrative and R&D costs.
Below are the company's financial results for the periods indicated:
SEC
As of September 30, 2023, the company only had $2,452 in cash and $3.1 million in total liabilities.
Telomir IPO details
TELO intends to sell one million shares of common stock at a suggested median price of $7.00 per share for gross proceeds of approximately $7.0 million, excluding the sale of customary underwriter options.
No existing shareholders have expressed interest in purchasing shares at the IPO price.
The Company is also registering approximately 6.2 million additional shares for sale by selling shareholders, which could negatively impact the post-IPO price of the stock if sold by selling shareholders in the open market during a concentrated period.
Assuming a successful IPO at the midpoint of the proposed price range, the Company's IPO enterprise value (excluding underwriter options) would be approximately $201.4 million.
The free float to shares outstanding ratio (excluding underwriter options) will be approximately 3.38%, making the stock essentially a “low float” stock subject to increased volatility post-IPO.
The company is also considered a “smaller reporting company” and an “emerging growth company,” so it may choose to provide significantly less information to shareholders.
The stocks of such companies have often performed poorly after going public.
Management says it will use the net proceeds from the IPO as follows:
approximately $2.0 million to fund our preclinical animal toxicology studies and CMC activities,
approximately $0.3 million for expenses related to our initial IND application and
approximately $0.7 million for expenses related to our Phase I clinical trials for TELOMIR-1; And
the remaining amounts are used to finance working capital and general corporate purposes.
(Source – SEC)
There is no presentation of the company roadshow by management.
Regarding outstanding litigation, management said there are no litigation cases that it believes would have a material adverse effect on the Company's operations or financial condition.
The only listed bookrunner for the IPO is Kingswood Investments.
Comment on Telomir Pharmaceuticals
Telomir is seeking U.S. public capital market investment to advance its preclinical drug development efforts.
Management believes the company's lead candidate, TELOMIR-1, has the potential to act as an interleukin-17 inhibitor, which could play a role in age-related inflammatory conditions such as “hemochromatosis and osteoarthritis, as well as post-chemotherapy health problems.”
The market opportunity for hemochromatosis treatment is under $1 billion and is expected to grow moderately in the coming years.
Management has not disclosed any collaborative or research relationships between major pharmaceutical companies.
The Company's investor syndicate does not include any known institutional life sciences venture capitalists or strategic investors.
The company has very little capitalization and is still in the preclinical development phase, so going public would be extremely risky.
As for valuation expectations, management is asking IPO investors to pay an enterprise value of $201 million, an extremely high valuation expectation for a preclinical-stage biopharma company.
Given the high risks, low stock, low capitalization, and management's extremely high valuation expectations, my opinion on the IPO is Sell. [Avoid].
Expected IPO pricing date: To be announced
Comments are closed.